The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection.

ABSTRACT: BACKGROUND:Direct-acting anti-viral (DAA) therapy may have a beneficial role in extrahepatic manifestations of hepatitis C virus (HCV) infection. However, the available data are limited. AIM:To examine the effects of DAA treatment on the risk of several extrahepatic manifestations of HCV. METHODS:We conducted a retrospective cohort study of patients from the US Department of Veterans Affairs Corporate Data Warehouse who had a positive HCV RNA test and received first course of DAAs between 2012 and 2016. We calculated incidence rates by sustained virological response (SVR) status for six extrahepatic manifestations, and effect of SVR on these conditions was evaluated in adjusted Cox regression models. RESULTS:Of the 45 260 patients treated with DAA with mean follow-up of 2.01 years, 41 711

SUBMITTER: El-Serag HB 

PROVIDER: S-EPMC6510621 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature